Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.
Follow-Up Questions
Who is the CEO of Impact Biomedical Inc?
Mr. Frank Heuszel is the Chairman of the Board of Impact Biomedical Inc, joining the firm since 2020.
What is the price performance of IBO stock?
The current price of IBO is $0.6633, it has increased 0.75% in the last trading day.
What are the primary business themes or industries for Impact Biomedical Inc?
Impact Biomedical Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Impact Biomedical Inc market cap?
Impact Biomedical Inc's current market cap is $8.0M
